Journal
MARINE DRUGS
Volume 9, Issue 6, Pages 1038-1055Publisher
MDPI AG
DOI: 10.3390/md9061038
Keywords
chitosan nanoparticles; adjuvant; immune response; ovalbumin
Categories
Ask authors/readers for more resources
The study was conducted to investigate the promoted immune response to ovalbumin in mice by chitosan nanoparticles (CNP) and its toxicity. CNP did not cause any mortality or side effects when mice were administered subcutaneously twice with a dose of 1.5 mg at 7-day intervals. Institute of Cancer Research (ICR) mice were immunized subcutaneously with 25 mu g ovalbumin (OVA) alone or with 25 mu g OVA dissolved in saline containing Quil A (10 mu g), chitosan (CS) (50 mu g) or CNP (12.5, 50 or 200 mu g) on days 1 and 15. Two weeks after the secondary immunization, serum OVA-specific antibody titers, splenocyte proliferation, natural killer (NK) cell activity, and production and mRNA expression of cytokines from splenocytes were measured. The serum OVA-specific IgG, IgG1, IgG2a, and IgG2b antibody titers and Con A-, LPS-, and OVA-induced splenocyte proliferation were significantly enhanced by CNP (P < 0.05) as compared with OVA and CS groups. CNP also significantly promoted the production of Th1 (IL-2 and IFN-gamma) and Th2 (IL-10) cytokines and up-regulated the mRNA expression of IL-2, IFN-gamma and IL-10 cytokines in splenocytes from the immunized mice compared with OVA and CS groups. Besides, CNP remarkably increased the killing activities of NK cells activity (P < 0.05). The results suggested that CNP had a strong potential to increase both cellular and humoral immune responses and elicited a balanced Th1/Th2 response, and that CNP may be a safe and efficacious adjuvant candidate suitable for a wide spectrum of prophylactic and therapeutic vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available